Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Costa, Daniel B., Kobayashi, Susumu, Tenen, Daniel G., Huberman, Mark S.·2007·Lung Cancer
DOI 10.1016/j.lungcan.2007.05.017

Cited by (160)

Items 101–160 of 160

  1. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
    Seung Tae Kim, Maruja Lira, Shibing Deng, Sujin Lee, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Mao Mao, Jin Seok Heo, Wooil Kwon et al. · 2015 · Oncotarget
  2. PharmGKB summary
    Uğur Hodoğlugil, Michelle Whirl‐Carrillo, Joan M. Hebert, Niki Karachaliou, Rafael Rosell, Russ Biagio Altman, Teri E. Klein · 2013 · Pharmacogenetics and Genomics
  3. Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy
    Lan Shao, Beibei Zhang, Chunxiao He, Baochai Lin, Zhengbo Song, Guangyuan Lou, Xinmin Yu, Yiping Zhang · 2014 · Chinese Medical Journal
  4. Improvement in population‐based survival of stage IV NSCLC due to increased use of chemotherapy
    Mieke Josepha Aarts, B.E. van den Borne, Bonne Biesma, Jeroen S. Kloover, Joachim G.J.V. Aerts, V.E.P.P. Lemmens · 2014 · International Journal of Cancer
  5. Implications of EGFR PharmDx™ Kit for cetuximab eligibility
    Christian Ensinger, William Sterlacci · 2008 · Expert Review of Molecular Diagnostics
  6. Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells
    Zhihong Xu, Wen-wen Shun, Junbiao Hang, Beili Gao, Jiaan Hu · 2015 · Tumor Biology
  7. Fluorometric detection of EGFR exon 19 deletion mutation in lung cancer cells using graphene oxide
    Dong‐Min Kim, Dong Ho Kim, Woong Jung, Kye Young Lee, Dong‐Eun Kim · 2018 · The Analyst
  8. In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbitux®) in a model of human non-small cell lung cancer expressing EGFR and HER2
    Giovanna Privitera, Tonia Luca, Nicolò Musso, Carlo Vancheri, Nunzio Crimi, Vincenza Barresi, D. F. Condorelli, Sergio Castorina · 2015 · Clinical and Experimental Medicine
  9. VLX1570 regulates the proliferation and apoptosis of human lung cancer cells through modulating ER stress and the AKT pathway
    Juan Wang, Tongde Du, Ya Lu, Yan Yun Lv, Yuxin Du, Jianzhong Wu, Rong Ma, Chenxin Xu, Jifeng Feng · 2021 · Journal of Cellular and Molecular Medicine
  10. EGF receptor in lung cancer: a successful story of targeted therapy
    Gelenis Calzadilla Domingo, Cesar A. Perez, Michel Velez, Jennifer Cudris, Luis Estuardo Raez, Edgardo S. Santos · 2010 · Expert Review of Anticancer Therapy
  11. A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer
    Shanchao Wu, Xinyi Zhou, Lili Ai, Yanxue Shang, Yuping Yan, Zilong Zhao, Weihong Tan · 2025 · ACS Nano
  12. Association between EGFR mutation and expression of BRCA1 and RAP80 innon-small cell lung cancer
    Xia Sun, Fangbo Cui, Huafang Yin, Dan Wu, Nanyao Wang, Ming Yuan, Yanhua Fei, Qiong Wang · 2018 · Oncology Letters
  13. IL-6/gp130/STAT3 Signaling Axis in Cancer and The Presence of In-Frame gp130 Somatic Deletions in Inflammatory Hepatocellular Tumors
    Rafael Rosell, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, Miquel Tarón · 2009 · Future Oncology
  14. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
    Cristina Pérez-Ramírez, Marisa Cañadas‐Garre, Miguel Ángel Molina‐Vila, María José Faus-Dáder, Miguel Ángel Calleja‐Hernández · 2015 · Pharmacological Research
  15. Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation
    Chuanqi Xie, Jindong Kong, Fujun Miao, Xuanjun Wang, Jun Sheng · 2020 · Thoracic Cancer
  16. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro
    Jing Wang, Hong Wei, Bao-Xia Zhao, Mei Li, Weipeng Lv, Ling Lv, Bo Song, Shen Lv · 2014 · Journal of Molecular Histology
  17. Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer
    Rafael Rosell, Teresa Morán, Santiago Viteri, Enric Carcereny, Amaya Gascó, Vanessa Quiroga, Jia Wei, Carlos Camps, Bartomeu Massutí · 2010 · Expert Opinion on Pharmacotherapy
  18. Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?
    Yafang Liu, Ze Xing, Ping Zhan, Hongbing Liu, Wei Ye, Tangfeng Lv, Yong Song · 2016 · Medicine
  19. First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan
    Chien-Hao Lie, Huang‐Chih Chang, Tung-Ying Chao, Yu‐Hsiu Chung, Jui-Long Wang, Chin‐Chou Wang, Meng‐Chih Lin · 2011 · Clinical Lung Cancer
  20. Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
    Seung Tae Kim, Won Jin Chang, Lihua Jin, Jae Sook Sung, Yoon Ji Choi, Yeul Hong Kim · 2015 · Cancer Research and Treatment
  21. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib
    Kailin Xing, Xiaoyan Zhou, Xinmin Zhao, Si Sun, Zhiguo Luo, Huijie Wang, Hui Yu, Jialei Wang, Jianhua Chang, Xianghua Wu et al. · 2014 · Medical Oncology
  22. Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?
    Rong Biaoxue, Yang Shuanying · 2018 · The International Journal of Biological Markers
  23. TASK‑1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial‑mesenchymal transition in lung cancer
    Xingguang Wang, Naxin Yuan, Xin‐Peng Li, Fangfang Chen · 2017 · Experimental and Therapeutic Medicine
  24. Chemotherapy combined with Endostar as salvage treatment for EGFR‐tyrosine kinase inhibitor primary resistance in an advanced non‐small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report
    Dong Qiu, Yu Zhang, Yingbo Xue, Qi Shen, Hang Li, Huang Ping, Jianjun Hu, Yong‐sheng Wang · 2019 · Thoracic Cancer
  25. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Therapy
    Suyon Chang, Jin Hur, Yoo Jin Hong, Hye‐Jeong Lee, Young Jin Kim, Kyunghwa Han, Byoung Wook Choi · 2017 · American Journal of Roentgenology
  26. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells
    Yichen Liang, Hongge Wu, Hong-jian Xue, Qing Liu, Liangliang Shi, Tao Liu, Gang Wu · 2013 · Journal of Huazhong University of Science and Technology [Medical Sciences]
  27. Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
    Hyojeong Kim, Tak Yun, Young Ju Lee, Ji‐Youn Han, Heung Tae Kim, Geon Kook Lee · 2013 · Journal of Korean Medical Science
  28. EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer
    Jin-Qiu Yuan, Yuelun Zhang, Haitao Li, Chen Mao · 2017 · Medicine
  29. Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review
    Fang Hu, Xiaowei Mao, Yujun Zhang, Xiaoxuan Zheng, Ping Gu, Huimin Wang, Xueyan Zhang · 2018 · OncoTargets and Therapy
  30. A validated high‐performance liquid chromatography–tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study
    Can Zhao, Nan Zheng, Fen Yang, Shuyan Han, Pingping Li · 2019 · Biomedical Chromatography
  31. Biomarkers for the targeted therapies of non-small cell lung cancer
    Antônio Rossi, Galetta · 2012 · Current Biomarker Findings
  32. Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis
    Xiaowei Mao, Yujun Zhang, Fangfang Xie, Xiaoxuan Zheng, Jiayuan Sun · 2017 · Oncotarget
  33. The Effectiveness and Safety of Integrative Traditional Asian Medicine Therapy in Lung Cancer Patients Undergoing Cancer Standard Treatment: A Protocol for Systematic Review and Meta-analysis
    K.S. Lee, Dong-Hyeon Kim, Sang‐Won Shin, Mi-Sun Park, Jieun Kwon, So-Jung Park · 2025 · Innovations in Acupuncture and Medicine
  34. Feasibility Re-evaluation of 75 mg/m2 Docetaxel in Japanese Patients with Previously Treated Non-small Cell Lung Cancer
    Kazuhiko Yamada, Hiroaki Takeoka, Y. Mizoguchi, Fumiya Yamashita, Tsukasa Yoshida, Yoshio Zaizen, Yusuke Okayama, Yoshiki Naito, K. Azuma, Tomoaki Hoshino · 2014 · Japanese Journal of Clinical Oncology
  35. Primary Pulmonary Neoplasms
    Jeremy J. Erasmus, Holman Page McAdams, Santiago Enrique Rossi · 2009 · Elsevier eBooks
  36. Response of Intracranial Metastases to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: It May All Depend on EGFR Mutations
    Daniel Botelho Costa, Susumu S. Kobayashi · 2008 · Journal of Clinical Oncology
  37. Historia del cáncer de pulmón: desde Doll y Hill hasta las terapias de precisión
    Oscar G. Arrieta, Andrés Felipe Cardona, Zyania Lucía Zatarain-Barron, Christian D. Rolfo, Camila Ordóñez‐Reyes, Alejandro Ruíz Patiño, Rafael Rosell · 2021 · Medicina
  38. Verifying the Role of Surgical Pathologists in the Precision Medicine of Lung Cancer
    Philip T. Cagle, Randall J. Olsen · 2012 · Archives of Pathology & Laboratory Medicine
  39. Epidermal Growth Factor Receptor Mutations as a Prognostic Factor in Korean Patients with Advanced Lung Adenocarcinoma Who Had Not Been Treated with Received Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Seung Tae Kim, Yoon Ji Choi, Kyong Hwa Park, Sang Cheul Oh, Jae Hong Seo, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim · 2011 · Chemotherapy
  40. Osimertinib-related skin and mucosal adverse events
    Juan Jose Garcia, Eudald Felip, Adrià Plana‐Pla, Aram Boada, Laura Angelats, M.J. Fuente, Enric Carcereny, Iris Teruel, Teresa Morán · 2017 · Cancer Treatment and Research Communications
  41. EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?
    Raffaele Califano, Fiona Helen Blackhall, Giovanna Finocchiaro, Luca Toschi, Nicholas J. Thatcher, Federico Cappuzzo, Lucio Crinò · 2008 · Targeted Oncology
  42. Cáncer de pulmón de célula no pequeña metastásico
    Carlos Castro, Andrés Felipe Cardona, Ludovic Revéiz, Silvia Juliana Serrano, Hernán Carranza, Carlos Alberto Vargas, Noemı́ Reguart, Felipe Campos, Édgar Guillermo Ospina, Oswaldo Sánchez et al. · 2019 · Acta Médica Colombiana
  43. Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?
    Pascale Tomasini, Laurent Greillier, Fabrice Barlési · 2012 · Current Respiratory Care Reports
  44. PHARMACOTHERAPY OF NON-SMALL CELL LUNG CANCER: A SHORT REVIEW
    Balaji Ommurugan · 2018 · Asian Journal of Pharmaceutical and Clinical Research
  45. Drug Resistance Prediction of Non-small Cell Lung Cancer Based on Deep Learning
    Tao Wei, Bijiang Li, Chan Liang, Xiaobo Zhang, Xuejun Zhang · 2020 · IEEE International Conference on Information Technology, Big Data and Artificial Intelligence (ICIBA)
  46. Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer
    Erminia Massarelli · 2014 · Lung Cancer
  47. Targeting the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kB) Pathway to Overcome Cisplatin-Resistance in Non-Small Cell Lung Cancer
    Sarah-Louise Ryan · 2019 · Queensland University of Technology
  48. EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer
    David A. Eberhard · 2008 · Humana Press eBooks
  49. Determinantes moleculares de resposta e resistencia aos inibidores da tirosina quinase (TKI) em pacientes com carcinoma de pulmão não pequenas celulas (CPNPC) com mutações no gene do recptor do fator de crescimento epidermico (EGFR)
    Daniel Botelho Costa · 2008
  50. Supervivencia en pacientes con adenocarcinoma de pulmón metastásico y registro de las primeras mutaciones en el receptor para el factor de crecimiento epidérmico documentado en Colombia Estudio del ONCOLGroup
    Jorge Miguel Otero, Andrés Felipe Cardona, Ludovic Revéiz, Felipe Campo, Hernán Carranza, Carlos A. Vargas, Esther Carrasco, Noemı́ Reguart, Mauricio Cuello, Oswaldo Sánchez et al. · 2009 · Redalyc (Universidad Autónoma del Estado de México)
  51. The biological importance of LRIG1 in lung cancer
    Samuel Kvarnbrink · 2012
  52. Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials
    Adnan Aydıner · 2012 · Journal of Cancer Therapy
  53. Progress in the Treatment of Metastatic Non–Small-Cell Lung Cancer: Slow but Steady!
    Nithya Ramnath, Ramaswamy Govindan · 2009 · Clinical Lung Cancer
  54. Non-genetic resistant mechanism to EGFR tyrosine kinase inhibitory therapy
    Samuel Zhixing Tan · 2015 · TSpace (University of Toronto)
  55. Lung Cancer
    Jeremy J. Erasmus, David J. Stewart, Ritsuko R. Komaki, Stephen G. Swisher · 2012 · Elsevier eBooks
  56. Lung Cancer
    Jeremy J. Erasmus, Quynh‐Nhu Nguyen, David J. Stewart, Stephen G. Swisher · 2022 · Elsevier eBooks
  57. Research on Drug Resistance of Non-Small Cell Lung Cancer Based on Deep Learning
    涛 韦 · 2020 · Computer Science and Application
  58. Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
    Feng-Wu Lin, Miao-Qing Zhao, Qiang Wu, Wenqi Wu, Xiao-Ying Wu, Ya Ma, Jia-Ni C. Yin, Meng Yang, Min Gao · 2025 · Genes, Chromosomes and Cancer
  59. Model-supported patient stratification using multi-objective synergy optimization in combination therapy
    Jana L. Gevertz, Irina Kareva · 2026 · Mathematical Biosciences
  60. Oncogenic drivers in cancer: Genomic alterations, molecular mechanisms, and targeted therapeutic strategies
    Sudarshan Rajput, Amrapali Mhaiskar, Ujashkumar A. Shah, Shaktipal Patil · 2026 · Pharmacological Research - Reports